Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Califf

Showing results (531-540 of 565) with videos related to

Pageof 57
Sort By:
American Heart Journal|December 25, 2015
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarctionSean D Pokorney, Christina Radder, Phillip J Schulte, et al.
Journal of the American College of Cardiology|December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.
American Heart Journal|September 11, 2013
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trialStephen E Kimmel, Benjamin French, Jeffrey L Anderson, et al.
Circulation|January 30, 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future DirectionsAbhinav Sharma, Neha J Pagidipati, Robert M Califf, et al.
JAMA|November 7, 2002
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trialA Michael Lincoff, Robert M Califf, Frans Van de Werf, et al.
Circulation. Cardiovascular Quality and Outcomes|March 1, 2012
Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS TrialMatthew T Roe, Jennifer A White, Padma Kaul, et al.
European Journal of Heart Failure|July 6, 2012
Troponin I in acute decompensated heart failure: insights from the ASCEND-HF studyG Michael Felker, Vic Hasselblad, W H Wilson Tang, et al.
Journal of the American College of Cardiology|April 18, 2015
Cardiovascular drug development: is it dead or just hibernating?Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 15, 2015
Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary SyndromesDavid A Zidar, Joseph C Mudd, Steven Juchnowski, et al.
The New England Journal of Medicine|June 4, 2015
Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesChristopher P Cannon, Michael A Blazing, Robert P Giugliano, et al.
Pageof 57

Showing results (531-540 of 565) with videos related to

Sort By:
Pageof 57
American Heart Journal|December 25, 2015
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarctionSean D Pokorney, Christina Radder, Phillip J Schulte, et al.
Journal of the American College of Cardiology|December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.
American Heart Journal|September 11, 2013
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trialStephen E Kimmel, Benjamin French, Jeffrey L Anderson, et al.
Circulation|January 30, 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future DirectionsAbhinav Sharma, Neha J Pagidipati, Robert M Califf, et al.
JAMA|November 7, 2002
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trialA Michael Lincoff, Robert M Califf, Frans Van de Werf, et al.
Circulation. Cardiovascular Quality and Outcomes|March 1, 2012
Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS TrialMatthew T Roe, Jennifer A White, Padma Kaul, et al.
European Journal of Heart Failure|July 6, 2012
Troponin I in acute decompensated heart failure: insights from the ASCEND-HF studyG Michael Felker, Vic Hasselblad, W H Wilson Tang, et al.
Journal of the American College of Cardiology|April 18, 2015
Cardiovascular drug development: is it dead or just hibernating?Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 15, 2015
Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary SyndromesDavid A Zidar, Joseph C Mudd, Steven Juchnowski, et al.
The New England Journal of Medicine|June 4, 2015
Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesChristopher P Cannon, Michael A Blazing, Robert P Giugliano, et al.
Pageof 57